Cultivating the Bioeconomy
SynBioBeta 2026
All good things must come to an end, as we close out the SynbioBeta2026 Summit, here are just a few reflections on what was a great week of science, technology and commercial applications. SynBioBeta, true to its mission, has evolved over the years. It is a positive sign to see both a greater presence of established bio/pharma/agtech companies in attendance, while still being a magnet to the startup bio community. Kudos to John Cumbers (I first met John at one of Craig Venter’s Genomes, Medicines and Environment conferences many years ago) and team for ‘cultivating’ a great event, and in the process not only keeping the SynBioBeta spirit alive, but also growing its reach, both in depth and breadth.
Too much to cover here in one post, but a few themes that stood out this week:
Resilience. This was the topic of my panel, and also a theme that was woven into many of the discussions throughout the week, both online and offline. The word has been around for as long as words have been around, but as it applies to biology and the bioeconomy, there are likely as many meanings as people you ask. At least for the bioeconomy perspective, resilience needs to be fused with opportunity - building a world that is not only defensive to shocks, but one that thrives in spite of them. From what I witnessed this week, some of the building blocks are in place.
The mix of early stage and incumbents. There is room for everyone to have a seat at the table, as long as information and idea exchange is open and acted upon. The incumbents know and recognize that acquiring nascent technologies and/or companies comes with challenges, but the ‘not built here’ mindset needs to go away, once and for all. Similarly, startups need to recognize that good science does not always translate to a good business, at least on its own. An ecosystem approach is starting to form, where several companies together might provide the requisite raw material for a commercially viable business case. More needs to be done, but things appear to be moving in a positive direction.
The role of the consumer. Just ‘building it and they will come’ may work for iPhones, but not necessarily for the bioeconomy. Consumers are more educated, more discerning, and more vocal about what they want, and maybe more importantly, what they don’t want. Companies ranging from Pharma to CPG have had to adjust their GTM strategies in recent years; however, in the long run as we are programming biology on a much larger commercial scale, consumers, companies and their suppliers will all be positoned to benefit.
And a few notable topical takeaways:
LLMs and World Models. LLMs trained on biological sequences and published scientific literature can compress the Design-Build-Test-Learn cycle that underpins almost every commercial bio program (*note, it was good to see the ‘Learn’ module really emphasized this year in the D-B-T-L sequence). This ranges from programmable RNA medicines and virtual cell models, to AI-designed enzymes, and proteins that replace artificial sweeteners. LLMs can not replace the investigators logic, but instead act as reasoning agents that propose constructs, plan experiments, and interpret multi-omics data far faster than human-only workflows. World models, operating as learned simulators of cells, tissues, ecosystems and even bioreactors, can stimulate potentially scalable experimentation and bioprocessing, and enable real-time monitoring for a cost-competitive production agenda, before committing capex to scale-up. In my view this is not an either-or pathway; it is comprised of both.
Synthetic Data. The lack of foundational data was an issue discussed again and again throughout the sessions, regardless of domain. While not a panacea, synthetic data can help to close biology’s chronic data-scarcity issue. The development and exploitation of synthetic data can fill a gap by letting generative models, virtual cells, and physics-based simulators produce labeled examples that biological foundation models need to generalize, in the process turning the AI-and-biology workflow into a self-reinforcing flywheel where models propose, simulators generate data, and the next model trains on richer ground truth. It is not a perfect solution, but it is a necessary one. An additional benefit is, strategically, synthetic data lowers the capital barrier that has historically kept synthetic biology a wet-lab-rich incumbent’s game.
Space. Space now has a legitimate seat at the table. This is probably the most compelling transition from science-fiction-to-science-fact. The BioSpace ‘space’ includes connections to hardware, software, and data. Orbital experimentation platforms are providing the bioeconomy access to microgravity, vacuum, and radiation regimes that yield higher-quality protein crystals, novel cell-therapy aggregates, and engineered materials impossible to produce on Earth. In-space biology cannot always operate with a human technician in the loop, so autonomous labs and experiment cycles are not just nice to have - they are necessary. Like many commercial space technologies, the benefits (of automation) invariably spill over into many other industries, launching new scientific and commercial applications. There are two (of many) notable space-derived data focus areas that come to mind that can help to accelerate the bioeconomy: (1) Earth-observation satellites which supply continuous, planetary-scale signals for feedstock sourcing, climate-driven supply-chain risk, agricultural yield and disease modeling, and (2) biosecurity surveillance for the Planetary Health track. The need for both will only increase with time.
And one of the most interesting sessions focused on Geopolitics and Biology. More on that later.
I also wanted to note that the SynBioBeta crew had a beautiful memorial to Dr. Craig Venter, who may be largely responsible for many of those in attendance for even being in the room. Zoom in on the image to view the ‘building blocks’ (the A C T G) of the image. The larger than life tribute was staged in the front of the exhibition hall, so while on stage one could see him gazing, even appearing to be listening to the discussions. It was very appropriate.
And as always it was great to meet new folks across all sectors of the bioeconomy, as well as to reconnect with some old faces - Andrew Hessel, Ryan Bethencourt and Drew Endy to name a few. It goes without saying that I am already looking forward to SynBioBeta2027.
As investor appetite across the Bioeconomy spectrum increases, Moby Market Intelligence has started to dig deeper into the technologies, market drivers, and related companies, providing research and market positioning views for investors who want to take advantage of these long-duration deeptech investment themes. As we spend a great deal of time thinking about economy-shifting investment cycles; the bioeconomy increasingly checks all of our boxes. Take a look at a couple of our public facing Market Intelligence letters (Longevity, Alive) and let us know what you think.